Aimmune Therapeutics (AIMT) Earns Buy Rating from Analysts at Wedbush

Wedbush assumed coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research report sent to investors on Wednesday morning. The firm issued a buy rating and a $72.00 price objective on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. BidaskClub cut Aimmune Therapeutics from a strong-buy rating to a buy rating in a report on Tuesday, June 19th. Roth Capital set a $80.00 target price on Aimmune Therapeutics and gave the stock a buy rating in a report on Tuesday, October 9th. Credit Suisse Group set a $40.00 target price on Aimmune Therapeutics and gave the stock a buy rating in a report on Monday, August 13th. ValuEngine cut Aimmune Therapeutics from a strong-buy rating to a buy rating in a report on Friday, September 7th. Finally, Cantor Fitzgerald set a $62.00 price target on Aimmune Therapeutics and gave the company a buy rating in a report on Monday, October 15th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $50.70.

Shares of NASDAQ AIMT opened at $27.29 on Wednesday. The firm has a market capitalization of $1.62 billion, a P/E ratio of -10.46 and a beta of -0.27. Aimmune Therapeutics has a 52-week low of $24.56 and a 52-week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.05). Analysts anticipate that Aimmune Therapeutics will post -3.64 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Xact Kapitalforvaltning AB purchased a new position in shares of Aimmune Therapeutics during the third quarter valued at $221,000. Atria Investments LLC purchased a new position in shares of Aimmune Therapeutics during the third quarter valued at $213,000. Northern Trust Corp grew its holdings in shares of Aimmune Therapeutics by 26.3% during the second quarter. Northern Trust Corp now owns 518,581 shares of the biotechnology company’s stock valued at $13,945,000 after buying an additional 108,034 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Aimmune Therapeutics by 9.1% during the second quarter. Bank of New York Mellon Corp now owns 171,766 shares of the biotechnology company’s stock valued at $4,619,000 after buying an additional 14,283 shares in the last quarter. Finally, Schroder Investment Management Group grew its holdings in shares of Aimmune Therapeutics by 50.2% during the second quarter. Schroder Investment Management Group now owns 44,136 shares of the biotechnology company’s stock valued at $1,207,000 after buying an additional 14,760 shares in the last quarter. Institutional investors and hedge funds own 78.14% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: How Buying a Call Option Works

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply